Purpose Midazolam metabolic clearance to 1′-hydroxymidazolam is an accurate measure of CYP3A activity which requires extensive plasma and urine sampling. The objective of this study was to find a new limited sampling strategy (LSS) to predict midazolam metabolic clearance to 1′-hydroxymidazolam and subsequently CYP3A activity in an easy and reliable way, reducing costs and labour. Methods The development of this LSS is based on data from an in vivo drug-drug interaction study carried out in our clinical research unit. Various partial AUCs of midazolam were calculated and correlated with metabolic clearance of midazolam to 1′-hydroxymidazolam by nonlinear regression. The correlation with highest r 2 values was chosen to predict the midazolam metabolic clearance. Statistical significance of this method was verified by calculating the 95% confidence interval of the differences (%) between predicted and measured metabolic clearance of midazolam to 1′-hydroxymidazolam. Results The midazolam partial AUC from 2 to 4 h after oral administration correlated best with metabolic clearance of midazolam to 1′-hydroxymidazolam with r 2 =0.9816. This partial AUC comprised four midazolam concentrations at 2, 2.5, 3 and 4 h after oral administration of a midazolam solution. The 95% confidence interval of the differences between predicted metabolic clearance and measured metabolic clearance of midazolam to 1′-hydroxymidazolam was −0.97 to +13.2.
Introduction
Cytochromes P (CYPs) 450 represent a multifaceted family of heme-containing enzymes belonging to the group of monooxygenases responsible for phase-1 metabolism. Mammalian cytochromes are membrane proteins that have an active part in biosynthesis and metabolism of many physiological active substances. Moreover these enzymes are capable of catalysing biotransformation and metabolism of substances of foreign origin including drugs and toxins [1] . Cytochrome P 450 3A (CYP3A) is the most abundant of the CYP enyzmes in the liver and the gut. It metabolises approximately 50% of currently available drugs and accounts for 30% of the total CYP enzymes in hepatic microsomes. A large number of drugs interfere with CYP3A as they may act as inducers, substrates or inhibitors of this enzyme.
Midazolam is often used as a probe drug to determine the activity of CYP3A [2] . Midazolam belongs to the benzodiazepines family and is frequently used for anaesthetic induction, narcotic premedication and sedation of patients prior to surgery or other invasive medical procedures. It is extensively metabolised by CYP3A to its primary metabolite, 1′-hydroxymidazolam, and to the minor metabolites 4′-hydroxymidazolam and 1, 4′-dihydroxymidazolam. Only 1% of midazolam is eliminated unchanged in urine. Its main urinary metabolite is 1′-hydroxymidazolam glucuronide, which amounts to 63-80% of the administered dose within 24 h. Conjugates of 4′-hydroxymidazolam and 1′,4′-dihydroxymidazolam amount to 3 and 1% in urine [3] . Orally administered midazolam is used to assess the total-intestinal and hepatic-CYP3A activity.
Usually, CYP3A activity is tested before and during treatment with a potential inducer or inhibitor. To assess the time course of inhibition or induction, frequent midazolam testing would be required. The most predictive and reliable parameter to assess CYP3A activity is the metabolic clearance to 1′-hydroxymidazolam [4] . To accomplish this, a full pharmacokinetic profile (AUC 0À1 ) and the urinary excretion of 1′-hydroxymidazolam and its glucuronide over at least 24 h after single dose administration are required. Hence the use of midazolam as a probe drug to determine the time course of CYP3A activity is very limited. A useful strategy for the clinical practice of CYP3A4 phenotyping might be to reduce the number of plasma samples while still maintaining accurate determination of CYP3A activity. It will then be possible to obtain CYP3A activity over many days and assess the time course of drug-drug interactions.
We here propose a new limited sampling strategy (LSS) to predict the midazolam metabolic clearance to 1′-hydroxymidazolam and subsequently CYP3A activity in an easy and reliable way using far fewer plasma samples and no urine sampling. Limited sampling is a useful strategy to simplify proceedings and reduce costs and labour. This is relevant for the clinical application of CYP3A phenotyping.
Methods
The development of this LSS is based on data of an in vivo drug-drug interaction study carried out at the clinical research unit of the Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg. In this study 12 participants were included. The protocol was approved by the competent authority (BfArM, Germany) and the Ethics Committee of the University of Heidelberg; written informed consent was obtained from each subject prior to study-related procedures. On the first occasion, the subjects received midazolam in order to determine the baseline metabolic clearance of midazolam to 1′-hydroxymidazolam. Thereafter efavirenz (400 mg p.o. once daily) was administered over 14 days to study the inducing effect of efavirenz on CYP3A. Midazolam was given orally on days 1 and 14 of this period. After an overnight fast, 3 mg midazolam (Dormicum ® Roche 5 mg/5 ml, solution for injection or infusion) were administered in 100 ml tap water. Four hours thereafter, a standard meal was provided for each subject. Blood samples were taken after midazolam at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8 and 10 h, and urine was collected completely over 24 h. Concentrations of midazolam and 1′-hydroxymidazolam in plasma and urine were quantified by high performance liquid chromatography coupled to tandem mass spectrometry after modification of a published method [5] as described elsewhere [6] . The LC/MS/MS system (Thermo Fisher, Dreieich, Germany) consisted of a Surveyor Plus HPLC System and a triple stage quadrupole mass spectrometer (TSQ 7000 with API-2 ion source and performance kit). For quantification of the drugs, a Phenomenex Max RP column (150 × 2 mm, 4 μm, Phenomenex, Aschaffenburg, Germany) with integrated guard column was used at 40°C for chromatographic separation. In order to predict metabolic clearance of midazolam to 1′-hydroxymidazolam, various partial midazolam AUCs were calculated and correlated with the metabolic clearance of midazolam to 1′-hydroxymidazolam. Stepwise multiple regressions were used to identify optimal time points and intervals of midazolam plasma concentrations. Standard pharmacokinetic parameters and partial AUCs (1-2, 1-3, 1-4, 2-4 and 1-6 h) after oral administration of midazolam were calculated by noncompartmental analysis using WinNonlin 5.2 (Pharsight, Mountain View, CA, USA). Midazolam concentrations were expressed per milligram dose of midazolam. Non-linear regressions were performed using Prism 5.03 (GraphPad Software, La Jolla, CA, USA).
From the following equations [7] , we derived a formula to calculate the metabolic clearance of midazolam to 1′-hydroxymidazolam using a partial AUC of midazolam. Clearance is defined as the removal of substance from blood, expressed as volume per unit time.
where Ae is the total eliminated drug, k is the elimination rate constant first order, A the amount of drug, V the volume of distribution, C the concentration, λ the reaction rate constant first order, CL the clearance and t is the time after medication. The total eliminated drug is consistent with the integral of Eq. (1):
where Ae 1 is the total eliminated drug until time point of infinity, AUC is the area under the curve, which is also equal to the systemically available dose (F×D):
where F is the bioavailability and D is the dose.
Clearance and AUC are inversely related, and almost no midazolam is excreted unchanged in urine. Hence, clearance can be replaced by metabolic clearance. By means of non-linear regression of various partial AUCs and metabolic clearance of midazolam to 1′-hydroxymidazolam (Prism 5.03), the factor A was calculated:
Using the best fit (highest r 2 ), the prediction of the metabolic clearance of midazolam to 1′-hydroxymidazolam from this partial AUC is calculated as:
In order to verify the statistical significance of this predictive method, the 95% confidence interval of the differences (%) between predicted metabolic clearance and measured metabolic clearance of midazolam to 1′-hydroxymidazolam was determined. Precision and bias were assessed by the Bland-Altman method [8] .
Results
All partial AUCs per milligram of midazolam for 1-2, 1-3, 1-4, 2-4 and 1-6 h after oral medication correlated with metabolic clearance of midazolam to 1′-hydroxymidazolam. The full plasma concentration time profile of midazolam is shown in Fig. 1 , and correlation results are shown in Table 1 . The correlation of partial AUC from 2 to 4 h with the measured metabolic clearance of midazolam to 1′-hydroxymidazolam showed the highest r 2 value (r 2 = 0.9816; Fig. 2 ). This partial AUC comprises four blood samples at 2, 2.5, 3 and 4 h after oral midazolam administration. The use of a further reduced number of plasma samples to calculate partial AUC resulted in weaker correlations (partial AUC of 2-4 h with three blood samples at 2, 3 and 4 h: r 2 =0.9062, and with two blood samples at 2 and 4 h: r 2 =0.8795). Based on this non-linear regression, the factor was calculated as A=5656. Therefore, the following formula predicts the metabolic clearance of midazolam to 1′-hydroxymidazolam and CYP3A activity:
The midazolam concentrations to calculate partial AUC have to be expressed per milligram dose of midazolam.
There is a strong relationship between the measured and predicted metabolic clearance of midazolam to 1′-hydroxymidazolam. Using linear regression, the regression coefficient was 0.98, P<0.0001. The 95% confidence interval of the differences between predicted metabolic clearance and measured metabolic clearance of midazolam to 1′-hydroxymidazolam (−0.97 to +13.2%) showed no significant difference. There was good precision and low bias of the predicted metabolic clearance of midazolam to 1′-hydroxymidazolam (Fig. 3) . In contrast, the 95% confi- dence interval of the differences between predicted metabolite clearance and measured metabolic clearance of midazolam to 1′-hydroxymidazolam using this partial AUC and fewer plasma samples showed a significant difference [95% confidence interval using three blood samples (2, 3, 4 h): +18.11 to +31.68%, and using two blood samples (2, 4 h): +13.33 to +28.71%].
Discussion
The aim of this investigation was to find a useful strategy which predicts CYP3A activity in an easy and reliable way and facilitates the clinical application of CYP3A phenotyping and the determination of the time course of drug-drug interactions. LSS has already been proven to be an effective tool for monitoring the safety and efficacy of chemotherapeutic agents by minimising the number of blood samples necessary to evaluate AUC [9] . It was first introduced in 1987 to minimise the number of plasma samples for measuring AUC of vinblastine. With only two time points, Ratain and Vogelzang were able to estimate total AUC using stepwise multiple regression analysis [10] . Since then various LSSs have been investigated for many drugs in order to simplify sampling procedures and minimise costs. Regarding midazolam and the activity of CYP3A, Rogers et al. found that neither single plasma concentrations of the metabolite 1′-hydroxymidazolam nor the ratio of 1′-hydroxymidazolam to midazolam can be used for predicting midazolam clearance in healthy subjects [11] . Another study was performed to investigate limitations of using a single post-dose midazolam concentration to predict CYP3A-mediated drug-drug interactions. The purpose was to assess the ability of a single midazolam concentration to predict midazolam AUC in the presence and absence of CYP3A modulation by Gingko biloba, which induces CYP3A. The study showed that optimum midazolam sampling times to predict AUC were different before or after Gingko biloba [12] . This approach is not useful for prospective clinical trials where CYP3A activity is to be determined. Another strategy is the use of saliva for CYP3A phenotyping using midazolam [10] . This method however requires numerous samples over at least 6 h and a very sensitive analytical method due to the very low concentrations in saliva [13] .
Midazolam pharmacokinetics is well known und understood. The primary metabolic pathway is the formation of 1′-hydroxymidazolam via CYP3A, which is subsequently conjugated and excreted in urine and accounts for >70% of the oral dose administered [4] . Hence, quantification of this pathway by the metabolic clearance of midazolam to 1′-hydroxymidazolam is the most suitable parameter for CYP3A activity. We investigated the correlations between various partial midazolam AUCs and metabolic clearance of midazolam to 1′-hydroxymidazolam in order to find a reliable method to predict midazolam metabolic clearance. When midazolam is administered as an oral solution, the best results were obtained using the midazolam partial AUC from 2 to 4 h comprising four plasma samples at 2, 2.5, 3 and 4 h after oral administration of midazolam. Resorption and distribution are fast after an oral solution and do not seem to influence the prediction of CYP3A activity when using plasma samples from 2 to 4 h after midazolam administration. The prediction of the metabolic clearance of midazolam to 1′-hydroxymidazolam is only valid for the study conditions described above and for healthy volunteers without any conditions which could modify the absorption, distribution, metabolism or excretion of drugs. However, this method might also be applied to patients with limited metabolism caused by liver diseases in order to identify drug-drug interactions. The alteration of CYP3A activity by the addition of a drug should also be valid in these patients with the limitation that the prediction of the metabolic clearance might not be accurate. Using four plasma samples to determine partial AUC instead of one single plasma concentration minimises errors in prediction of CYP3A activity due to imprecisions of the analytical measurements.
General prediction of CYP3A activity has to comprise a full range of metabolic activity, including induction, inhibition and normal state of enzyme activity. Although this LSS is derived solely from induced and normal CYP3A activity, it is clear from Fig. 2 that inhibition of CYP3A activity will result in high partial AUCs and very low metabolic clearance approaching zero when there is no metabolic activity.
Conclusion
We propose a new LSS to predict midazolam metabolic clearance to 1′-hydroxymidazolam and thus CYP3A activity using a full pharmacokinetic dataset from an interaction study. The determination of the partial AUC from 2 to 4 h after oral administration of midazolam predicts CYP3A4 activity with high precision and will enable the assessment of the time course of drug-drug interactions and the clinical application of CYP3A4 phenotyping.
